# Za Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/za-biomedical

- Industry: Biotechnology
- Headquarters: Zhuhai, China
- Website: www.wnlbiomed.com
- Latest round: Series A (Sep 15, 2022)
- Investors on record: 2

## About

Founded in 2018 and based in Zhuhai, China, Za Biomedical is a biomedical company that focuses on the research and development of drugs for the treatment of skin cancer, cervical cancer and liver cancer. In 2021, the company established the subsidiary Guangao Biomedical Technology (Zhuhai) Co., Ltd. Xiaosong Liu, the founder and CEO of the company, has participated in or presided over research projects or major projects funded by the NIH in the United States, NHMRC in Australia, the National Natural Science Foundation of China, and the Guangdong Provincial Department of Science and Technology. In September 2022, Za Biomedical closed series A funding from new investors Zhongshan Huaying Healthcare Fund and Cheng Du Sheng Nuo Biotec Co., Ltd, and other investors. In September 2025, Za Biomedical continue to complete series A+ funding.

The company's main products include anti-multidrug-resistant bacteria polypeptide ointment, melanoma treatment polypeptide ointment and cervical cancer therapeutic vaccine. Cervical cancer therapeutic vaccines kill tumor cells by stimulating specific T-cell immune responses. Its products are used in skin cancer, cervical cancer, liver cancer and other diseases caused by malignant human papilloma (HPV) virus. The company generates revenue from providing medicines products.

## Funding rounds

- Series A, Sep 15, 2022 — Cheng Du Sheng Nuo Biotec Co.,Ltd, Zhongshan Torch Electronics Industry Fund Management

## Investors

- Cheng Du Sheng Nuo Biotec Co.,Ltd — Series A
- Zhongshan Torch Electronics Industry Fund Management (https://capitalatlas.ai/funds/zhongshan-torch-electronics-industry-fund-management) — Series A